微波治疗儿童皮肤血管瘤疗效观察

我们应用WNZ-1CDⅡ多功能微波治疗机(电子工业部生产)治疗了28例儿童皮肤血管瘤患者,取得良效,报告如下: 1 临床资料 28例确诊为皮肤血管瘤的患者中,草霉状血管瘤20例,海绵状血管瘤8例。其中男11例,女17例。年龄6个月～9岁。头面部12例,躯干11例,四肢4例,臀部1例。     

胶原贴敷料对面部轻度痤疮的屏障功能作用观察

目的评价胶原贴敷料对面部轻度痤疮患者面部屏障功能的作用,同时观察痤疮皮损、炎症后色素沉着的变化。方法对36例患有面部轻度痤疮的受试者,采用自身左右面部对比的方法,采用胶原贴敷料治疗。在治疗前、治疗1周和治疗4周对面部皮肤角质层含水量、经皮水分丢失、皮脂量、皮肤颜色进行测试;采用炎症性皮损和粉刺计数判定痤疮皮损改善情况。结果患者治疗侧面部皮肤角质层含水量显著升高（P〈0．05）;经皮水分丢失明显下降（P〈0．01）,治疗侧发生皮肤红斑,粗糙和脱屑低于对照侧面部皮肤。治疗侧炎性丘疹数目减少,红斑指数下降,但与对照侧相比无统计学差异。所有受试者均未出现不良反应。结论胶原贴敷料单独使用可促进轻度痤疮患者的面部屏障功能的修复,同时对于炎症性皮损、皮肤红斑反应有一定的抑制作用。     

红、蓝光照射联合胶原贴敷料治疗痤疮疗效观察

目的 观察红蓝光照射联合胶原贴敷料治疗寻常痤疮的临床疗效和安全性.方法 将113例痤疮患者分为两组,观察组采用胶原贴敷料联合红蓝光照射治疗,对照组采用冷模粉联合红蓝光照射治疗.结果 观察组和对照组有效率分别为82.76%和平58.18%,两组的治疗有效率存在差异(P＜0.01).结论 红蓝光联合胶原贴敷料治疗痤疮疗效确切.     

强脉冲光联合胶原贴敷料治疗面部激素依赖性皮炎临床观察

目的:观察强脉冲光联合胶原贴敷料治疗面部激素依赖性皮炎的临床疗效。方法:将入选的72例患者随机分为治疗组(37例)和对照组(35例)。两组均予口服依匹斯汀10 mg,每日1次;强脉冲光治疗,每3周1次,共4次。治疗组前两周同时给予胶原贴敷料每晚1次,继而隔天使用一次共12周。对照组予强脉冲光治疗后不予外部护理治疗。在第4周、8周、12周、结束后12周观察疗效。结果:治疗组8周、12周、结束后12周有效率分别为81.08%、86.49%、83.78%,优于对照组,差异有统计学意义(P<0.01)。治疗组12周时各项皮损评分均较治疗前明显好转,差异有统计学意义(P值均<0.01);对照组12周时除脓疱、皮肤萎缩评分外,红斑、脱屑、丘疹等较治疗前无明显好转(P值均<0.01)。结论:强脉冲激光联合胶原贴敷料治疗面部激素依赖性皮炎疗效好,值得临床推广应用。     

红蓝光照射联合胶原贴敷料治疗寻常痤疮疗效观察

目的观察红蓝光照射联合胶原贴敷料治疗寻常痤疮疗效和安全性。方法126例寻常痤疮患者随机分成两组,试验组采用红蓝光照射联合胶原贴敷料治疗,对照组采用红蓝光照射治疗。结果治疗4周后试验组和对照组患者有效率分别为93．9％和73．3％,差异有统计学意义（P〈0．01）。结论红蓝光照射联合胶原贴敷料治疗寻常痤疮安全有效。     

微晶磨削术联合胶原贴敷料治疗面部痤疮疗效观察

我科于2011年8月至2012年10月采用微晶磨削术联合胶原贴敷料（广州创尔生物技术有限公司生产）外用治疗痤疮,取得满意疗效,现报道如下。     

调Q开关激光联合胶原贴冷敷膜治疗黄褐斑的疗效观察

目的:探讨调Q开关激光联合胶原贴冷敷膜外敷及谷胱甘肽、维生素C静脉点滴治疗黄褐斑及术后色素沉着预防的应用效果。方法:选取我科黄褐斑激光治疗门诊患者112例,随机分为观察组和对照组各56例。对照组采用大光斑低能量调Q开关Nd∶YAG激光治疗,每周1次,连续10次,每次术后立即以移动性冰垫冰敷皮肤30 min,并在首次激光术后予静脉滴注谷胱甘肽联合维生素C治疗,每日1次,共14次为1疗程,间隔6月后开始第2疗程,共2疗程。观察组在对照组的基础上,激光术后即刻于患处外敷胶原贴冷敷膜再以移动性冰垫冰敷30 min,术后每日使用冷藏好的胶原贴冷敷膜护理面部,每次30 min,每日1次,共治疗10周,其余同对照组。于首次治疗3个月、9个月、1年后对所有患者进行门诊随访,对患者黄褐斑的疗效及色素沉着进行评估,比较两组疗效。结果:1年后,观察组总有效率为82.14%,对照组为57.14%,两组比较差异有统计学意义(χ~2=14.74,P<0.05)。观察组色素沉着发生率(5.36%)与对照组(30.36%)比较,差异有统计学意义(χ~2=21.65,P<0.05)。结论:调Q开关激光联合胶原贴冷敷膜外敷及谷胱甘肽、维生素C静脉点滴是治疗黄褐斑及预防术后色素沉着的有效方法,疗效明确。     

微等离子体射频技术联合胶原贴敷料治疗痤疮凹陷性瘢痕的临床观察

目的:观察微等离子体射频联合胶原贴敷料治疗痤疮凹陷性瘢痕的临床疗效。方法:收集面部凹陷性痤疮瘢痕患者108例,随机分为实验组和对照组。实验组54例,采用微等离子体射频联合胶原贴敷料治疗,对照组54例,仅采用微等离子体射频治疗。4次为一个疗程,每次间隔6周。观察两组患者的临床疗效、ECCA评分及不良反应发生情况。结果:治疗4次以后,实验组总有效率高于对照组,ECCA评分明显低于对照组,差异均有统计学意义(P值均<0.05)。不良反应方面,两组患者术后色沉发生率比较,差异无统计学意义(P>0.05);术后面部皮肤敏感发生率比较,差异有统计学意义(P<0.05)。结论:微等离子体射频技术对于痤疮凹陷性瘢痕疗效满意,但由于治疗后患者皮肤屏障可受到一定程度的损伤,故联合胶原贴敷料治疗痤疮凹陷性瘢痕疗效更佳,且术后皮肤敏感发生率降低,值得在临床推广运用。     

希睿达化学换肤联合胶原贴敷料治疗轻中度痤疮临床观察

目的 观察希睿达化学换肤联合胶原贴敷料治疗轻中度痤疮临床效果.方法 选择2019年1月至6月某医院治疗的轻中度痤疮125例作为研究对象,利用随机数字表法将其分为对照组(62例)和观察组(63例).对照组采用阿达帕林凝胶治疗,观察组采用希睿达复合酸联合胶原贴敷料治疗,比较两组治疗效果、治疗4周和治疗8周的痤疮体积V值减小...     

胶原贴敷料治疗接触性皮炎的临床观察

接触性皮炎是皮肤或黏膜单次或多次接触外源性物质后,在接触部位发生的炎症性反应。表现为红斑、肿胀、丘疹、水疱、甚至大疱[1]。2011年5月至2011年10月,应用胶原贴敷料(商品名:创福康,广州创尔生物技术有限公司出品)作为湿敷剂治疗接     

透明质酸修护贴敷料用于Q开关激光术后创面修复的临床观察

目的 探讨透明质酸修护贴敷料在Q开关激光术后皮肤创面修复中的有效性和安全性。方法面部色素性疾病患者66例,用Q开关脉冲激光治疗后,将患者分为试验组（22例）、对照组A（22例）和对照组B（22例）。试验组使用透明质酸修护贴敷料,对照组A用活泉水面膜,对照组B用蒸馏水面膜。激光术后即刻外敷受试品或对照品15 min,以后每晚外敷15 min,连续14 d;分别于激光术后首日、第3、7、14天对受试部位红斑、水肿、灼热等炎症反应进行半定量判定。同时比较3组患者创面恢复时间及对敷料的满意度。结果 透明质酸修护贴敷料和活泉水面膜改善激光术后皮肤红斑、水肿、灼热等症状优于蒸馏水面膜（P < 0.05）。激光术后,患者创面清洁度、湿润度、光滑度、舒缓程度和总体满意度,透明质酸修护贴敷料优于活泉水面膜和蒸馏水面膜（P < 0.05）。结论 透明质酸修护贴敷料用于激光术后护理可改善急性炎症反应、提高创面清洁度、湿润度、光滑度。     

Flashlamp-pumped pulsed dye laser for hemangiomas in infancy: treatment of superficial vs mixed hemangiomas

OBJECTIVE: To study in a compared manner the efficacy of flashlamp-pumped pulsed dye laser (FPDL) therapy for superficial and mixed hemangiomas. DESIGN: Nonrandomized control trial. SETTING: Department of Lasermedicine, General Hospital Neuk?lln, Berlin, Germany. PATIENTS: To investigate variation in response to treatment, a prospective study of 165 children with 225 separate hemangiomas treated with the FPDL was undertaken. Patients were aged 2 days to 7 years; mean follow-up was 5 months. INTERVENTIONS: During a 2 1/2-year period, we administered 332 treatments, for a mean+/-SD of 2.0+/-1.1 treatments per patient. MAIN OUTCOME MEASURE: Patients received therapy until the lesion was almost clear or until the lesion did not respond to treatment. Evaluation was performed by comparing pretreatment and posttreatment photographs. In addition, pathologic flow of vessels and thickness were determined before, during, and after completion of therapy with color-coded duplex sonography. RESULTS: In the first group of 100 patients with 153 flat cutaneous hemangiomas, 52 hemangiomas (34%) had excellent results; 80 (52%) had good results; and 21 (14%) showed proliferation of the subcutaneous component, although these lesions were flat at first presentation. Of the 54 mixed hemangiomas, 33 (61%) had continued proliferation of the subcutaneous component. The cutaneous component responded to therapy in 21 hemangiomas (39%), whereas the subcutaneous component of the mixed hemangiomas remained unchanged. No lesions in this group involuted completely, and therapy was discontinued because of relatively poor response. Twelve (67%) of 18 patients with superficial hemangiomas in the involution phase had excellent results and 6 (33%) had good results. CONCLUSIONS: Treatment with the FPDL is effective and may be the treatment of choice for superficial cutaneous hemangiomas at sites of potential functional impairment and on the face. Hemangiomas with a deep component do not benefit from FPDL treatment because the efficacy of the FPDL is limited by its depth of vascular injury. Furthermore, early therapeutic intervention with the FPDL may not prevent proliferative growth of the deeper or subcutaneous component of the hemangioma despite early intervention.     

Capillary hemangiomas and treatment with the flash lamp-pumped pulsed dye laser

Strawberry, or capillary, hemangiomas are common vascular neoplasms, with an incidence of approximately 2.6% in neonates. They usually develop in the first few weeks of life, so that between 1 month and 1 year the incidence rises to between 8.7% and 10.1%. These lesions may grow quite large in the first year of life, and they may ulcerate or obstruct a vital organ or function. The great majority will spontaneously regress after the first year of life. Parents are often alarmed at the sight of these hemangiomas and need reassurance that the great majority will regress spontaneously. Treatments such as cryosurgery, irradiation, radium instillation, corticosteroid therapy, or surgical excision are often ineffective or cause significant morbidity. We describe 10 children with capillary hemangiomas treated with the flash lamp-pumped pulsed dye laser. The patients ranged in age from 7 weeks to 5.5 years at the beginning of laser therapy. The patients underwent 3.1 +/- 1 (mean +/- SD) laser treatments, with a mean regression of the lesions of 69.9% +/- 4.5%. All patients demonstrated some diminution in the size and color of their hemangiomas after the treatments, and there were no ill effects, such as ulceration, hemorrhage, infection, or scarring. There was no evidence of hyperpigmentation or hypopigmentation. Pulsed dye laser therapy should be considered as an option in the treatment of capillary hemangiomas, preferably prior to their full evolution. It is also a useful therapeutic approach in those hemangiomas that are slow to regress in older children.     

Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas

Multiple cutaneous infantile hemangiomas have been associated with hepatic hemangiomas. Screening of infants with five or more cutaneous infantile hemangiomas with abdominal ultrasound is often recommended. The aim of this study was to determine the frequency with which hepatic hemangiomas occur in infants with five or more cutaneous infantile hemangiomas compared to those with one to four cutaneous infantile hemangiomas and to characterize the clinical features of these hepatic hemangiomas. A multicenter prospective study of children with cutaneous infantile hemangiomas was conducted at pediatric dermatology clinics at Hemangioma Investigator Groups sites in the United States, Canada, and Spain between October 2005 and December 2008. Data were collected, and abdominal ultrasonography was performed on infants younger than 6 months old with five or more cutaneous infantile hemangiomas and those with one to four cutaneous infantile hemangiomas. Twenty-four (16%) of the 151 infants with five or more cutaneous infantile hemangiomas had hepatic hemangiomas identified on abdominal ultrasound, versus none of the infants with fewer than five (p = 0.003). Two of the 24 infants with hepatic hemangiomas received treatment specifically for their hepatic hemangiomas. Infants with five or more cutaneous infantile hemangiomas have a statistically significantly greater frequency of hepatic hemangiomas than those with fewer than 5. These findings support the recommendation of five or more cutaneous infantile hemangiomas as a threshold for screening infants younger than 6 months old for hepatic hemangiomas but also demonstrate that the large majority of these infants with hepatic hemangiomas do not require treatment.     

Management of cutaneous hemangiomas in pediatric patients

Cutaneous hemangiomas (CHs) are common benign vascular tumors of childhood. Clinically, they are characterized by a typical evolution profile, consisting of a rapid proliferation during the first year of life and slow involution that usually is completed by 5 to 10 years of age. In most cases, no treatment is necessary. However, when CHs are located in areas at risk for functional complications; are of considerable size; or repeatedly undergo bleeding, ulceration, or superinfection, a prompt and adequate treatment approach is required. First-line approaches include topical, intralesional, and systemic corticosteroids. Second-line options include interferon alfa-2a and -2b, laser therapy, and surgical therapy. Third-line approaches include cytotoxins, embolization, and angiogenesis inhibitors. Other therapies and procedural approaches including intermittent pneumatic and continuous compression; cryosurgery; radiotherapy; implantation of copper needles; sclerotherapy; electrocautery; electroacupuncture; imiquimod cream 5%; and prospective agents, such as OXi4503 (diphosphate prodrug of combretastatin A1) and cidofovir, are discussed. Treatment options for ulcerated CHs also are described.     

红蓝光联合胶原蛋白敷贴治疗寻常痤疮疗效观察

目的:评价红蓝光照射联合胶原蛋白敷贴治疗寻常痤疮的疗效。方法:1013例寻常痤疮患者随机分为实验组(60例)与对照组(40例),两组均采用红、蓝光交替照射面部,另实验组外敷胶原蛋白敷贴,治疗4周观察两组的疗效。结果:实验组和对照组有效率分别为100%和90%,差异有统计学意义(x~2=6.59,P0.05)。结论:红蓝光交替照射联合胶原敷料敷贴治疗寻常痤疮,疗效明显优于单纯照射红蓝光。     

The treatment of cutaneous telangiectasia with the argon laser

The argon laser is of considerable value in the treatment of port wine stains. It is also a useful tool for the treatment of other vascular anomalies. We report our experience with 31 patients.
A variety of lesions were treated: post-radiation telangiectasia (2 patients); adenoma sebaceum (1); spider naevi (II); post rosacea telangiectasia of the nose (3); arborizing telangiectasia of the legs (4); venous flares of the legs (5); angiokeratoma of the thigh (1); and a miscellaneous group (4).
The patients have been followed up for between 6 and 24 months. Good results were obtained in patients with spider naevi and arborizing telangiectasia of the legs. Satisfactory results were seen in patients with post rosacea nasal telangiectasia, angiokeratoma of the thigh and in post-radiation telangiectasia. The argon laser was found not to be useful in the majority of patients with venous flares of the legs.
Hypopigmentation and mild skin atrophy was seen as a result of the laser treatment in four patients only. In none of the patients was there appreciable scarring.